AlgiPharma presenting at Formulation and Delivery 2024, London, UK
AlgiPharma presenting at Formulation and Delivery 2024, London, UK
We are delighted to have been invited to speak at the Formulation & Delivery 2024 conference, taking place 25th – 26th April in London, UK.
AlgiPharma will have two separate presentations highlighting it’s alginate technology for use in the drug delivery of lipid nanoparticles by inhalation and for oral uptake of peptides. Presentations will be by our Chief Scientific Officer, Dr. Philip Rye, and Chief Medical Officer, Dr. Yngve Mikkelsen.
Join us in London next week or follow up with us directly to get a copy of the presentations and explore commercial opportunities.
About AlgiPharma AS:
AlgiPharma AS is a clinical stage pharmaceutical company, founded in 2006 on decades of research and development carried out by FMC BioPolymer AS and the Institute of Biotechnology at the Norwegian University of Science and Technology (NTNU) in Trondheim, Norway. AlgiPharma has completed 5 clinical trials with two formulations of its lead drug candidate, OligoG, to treat respiratory symptoms of cystic fibrosis. AlgiPharma is developing its proprietary alginate technology for:
- Delivery platforms for nanoparticles, small and large molecule based drugs.
- Drug conjugates, adding functionality and reducing toxicity of parent compound.
- API in disease areas such as cystic fibrosis, COPD, and infectious diseases.
AlgiPharma has pharmaceutical scale production capabilities for its technology protected by a broad family of patents.
AlgiPharma owns or licenses all relevant patents upon which the technology platform and products are developed. The company is supported by national and international research programs, and collaborates with a network of key opinion leaders, highly recognized academic institutions, research and patient organizations in Europe and USA.
AlgiPharma has received more than USD 46 million in research and development grants from EU’s 7th framework program, Horizon 2020, and Eurostars programs, the Norwegian Research Council, Innovate UK, Innovation Norway, US Army through Congressional Earmark funding, the Australian R&D Tax Incentive, and the Cystic Fibrosis Foundation (CFF).
AlgiPharma is a privately owned company registered and domiciled in Norway.
For additional information contact:
Yngvar P. Berg, CEO: yngvar.berg@algipharma.com
Arne Dessen, COO and Chairman of the Board: arne.dessen@algipharma.com
